217 related articles for article (PubMed ID: 9233615)
1. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease.
Williamson E; Garside P; Bradley JA; More IA; Mowat AM
J Immunol; 1997 Aug; 159(3):1208-15. PubMed ID: 9233615
[TBL] [Abstract][Full Text] [Related]
2. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease.
Via CS; Rus V; Gately MK; Finkelman FD
J Immunol; 1994 Nov; 153(9):4040-7. PubMed ID: 7930611
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells.
Rus V; Svetic A; Nguyen P; Gause WC; Via CS
J Immunol; 1995 Sep; 155(5):2396-406. PubMed ID: 7650373
[TBL] [Abstract][Full Text] [Related]
4. Roquinimex-mediated protection effect on the development of chronic graft-versus-host disease in mice is associated with induction of Th1 cytokine production and inhibition of proinflammatory cytokine production.
Xiao ZY; Zhou WX; Zhang YX; Cheng JP; He JF; Yang RF; Yun LH
Life Sci; 2007 Oct; 81(19-20):1403-10. PubMed ID: 17950363
[TBL] [Abstract][Full Text] [Related]
5. IL-12 is a central mediator of acute graft-versus-host disease in mice.
Williamson E; Garside P; Bradley JA; Mowat AM
J Immunol; 1996 Jul; 157(2):689-99. PubMed ID: 8752918
[TBL] [Abstract][Full Text] [Related]
6. Administration of an IL-12-encoding DNA plasmid prevents the development of chronic graft-versus-host disease (GVHD).
Okubo T; Hagiwara E; Ohno S; Tsuji T; Ihata A; Ueda A; Shirai A; Aoki I; Okuda K; Miyazaki J; Ishigatsubo Y
J Immunol; 1999 Apr; 162(7):4013-7. PubMed ID: 10201922
[TBL] [Abstract][Full Text] [Related]
7. The flavonoid Kaempferol suppresses the graft-versus-host reaction by inhibiting type 1 cytokine production and CD8+ T cell engraftment.
Okamoto I; Iwaki K; Koya-Miyata S; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Clin Immunol; 2002 May; 103(2):132-44. PubMed ID: 12027418
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
9. The nephritogenic T cell response in murine chronic graft-versus-host disease.
Meyers CM; Tomaszewski JE; Glass JD; Chen CW
J Immunol; 1998 Nov; 161(10):5321-30. PubMed ID: 9820505
[TBL] [Abstract][Full Text] [Related]
10. Differential cytokine expression in acute and chronic murine graft-versus-host-disease.
Allen RD; Staley TA; Sidman CL
Eur J Immunol; 1993 Feb; 23(2):333-7. PubMed ID: 8436168
[TBL] [Abstract][Full Text] [Related]
11. [A role for T-helper type 1 and type 2 cytokines in the pathogenesis of various human diseases].
Kasakura S
Rinsho Byori; 1998 Sep; 46(9):915-21. PubMed ID: 9800477
[TBL] [Abstract][Full Text] [Related]
12. Allosuppressor- and allohelper-T cells in acute and chronic graft-vs-host disease. IV. Activation of donor allosuppressor cells is confined to acute GVHD.
Pals ST; Radaszkiewicz T; Gleichmann E
J Immunol; 1984 Apr; 132(4):1669-78. PubMed ID: 6230390
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
Via CS; Rus V; Nguyen P; Linsley P; Gause WC
J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
[TBL] [Abstract][Full Text] [Related]
15. Modulation of acute graft-versus-host disease and chimerism after adoptive transfer of in vitro-expanded invariant Valpha14 natural killer T cells.
Kuwatani M; Ikarashi Y; Iizuka A; Kawakami C; Quinn G; Heike Y; Yoshida M; Asaka M; Takaue Y; Wakasugi H
Immunol Lett; 2006 Jul; 106(1):82-90. PubMed ID: 16806496
[TBL] [Abstract][Full Text] [Related]
16. Adoptive transfer of small numbers of DX5+ cells alleviates graft-versus-host disease in a murine model of semiallogeneic bone marrow transplantation: a potential role for NKT lymphocytes.
Margalit M; Ilan Y; Ohana M; Safadi R; Alper R; Sherman Y; Doviner V; Rabbani E; Engelhardt D; Nagler A
Bone Marrow Transplant; 2005 Jan; 35(2):191-7. PubMed ID: 15558045
[TBL] [Abstract][Full Text] [Related]
17. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.
Blazar BR; Jenkins MK; Taylor PA; White J; Panoskaltsis-Mortari A; Korngold R; Vallera DA
J Immunol; 1997 Dec; 159(12):5821-33. PubMed ID: 9550378
[TBL] [Abstract][Full Text] [Related]
19. H1521, a novel derivative of 4-hydroxyquinoline-3-carboxamide, suppresses the development of lupus in mice by inducing Th1 cytokine profile in T cells.
Xiao ZY; Chen SH; Zhou WX; Zhang YX; Cheng JP; Yang RF
Int Immunopharmacol; 2011 Apr; 11(4):435-43. PubMed ID: 21195814
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of T cell activation in acute and chronic forms of murine graft-versus-host disease.
Via CS
J Immunol; 1991 Apr; 146(8):2603-9. PubMed ID: 2016521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
